Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. hormone based
Show results for
Products
Services

Companies

News

Refine by
Date

  • Older

Hormone Based Articles & Analysis

7 news found

Bayer progressing well with transformation of pharma business and raises peak sales potential of key growth drivers to over twelve billion euros

Bayer progressing well with transformation of pharma business and raises peak sales potential of key growth drivers to over twelve billion euros

Its market share in the US has already expanded to over 30 percent in non-metastatic castration-resistant prostate cancer (nmCRPC) and it has gained US label extension to treat patients in the metastatic hormone-sensitive prostate cancer (mHSPC) setting based on the strong data of the ARASENS study. ...

ByBayer AG


Gesynta Pharma prepares Phase II study of GS-248 in endometriosis following ground-breaking data from a preclinical proof-of-concept study

Gesynta Pharma prepares Phase II study of GS-248 in endometriosis following ground-breaking data from a preclinical proof-of-concept study

Available therapeutics for endometriosis are mainly hormone-based and aim to reduce the effect of endogenous estrogen. Therefore, hormonal contraceptives, as well as agents which completely shut off estrogen production, are often used. However, interfering with the normal female hormone levels often lead to side effects and such ...

ByGesynta Pharma AB


Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX Test

Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX Test

Approximately one-third of patients diagnosed with hormone receptor (HR)-positive, HER2- negative early breast cancer have a tumor that has spread to their lymph nodes. ...

ByExact Sciences UK, Ltd.


RxPONDER Study Results Demonstrate that the Oncotype DX Test Can Now Spare Chemotherapy Use in the Majority of Women with Node-positive Early-stage Breast Cancer

RxPONDER Study Results Demonstrate that the Oncotype DX Test Can Now Spare Chemotherapy Use in the Majority of Women with Node-positive Early-stage Breast Cancer

RxPONDER showed a different effect of chemotherapy based on Recurrence Score results for postmenopausal and premenopausal women. ...

ByExact Sciences UK, Ltd.


New Oncotype DX Real-World Evidence Shows for the First Time the Practice-Changing Impact of TAILORx Results

New Oncotype DX Real-World Evidence Shows for the First Time the Practice-Changing Impact of TAILORx Results

Of the 155 patients treated in Brazil between August 2018 and April 2019, 70% were classified as having high-risk disease based on traditional clinical parameters, and the majority had tumours larger than 2 centimeters. A total of 151 of the 155 patients (97%) were initially recommended chemotherapy in addition to hormonal therapy based on ...

ByExact Sciences UK, Ltd.


Microneedle patch technology shows potential for long-acting contraception

Microneedle patch technology shows potential for long-acting contraception

In the study conducted in animals, microneedle patches were designed to allow microneedles containing the contraceptive hormone levonorgestrel to break off their base within a few seconds following microneedle patch application to skin and, then, to slowly dissolve and deliver levonorgestrel for over a month with a single microneedle patch application. ...

ByMicron Biomedical, Inc.


New Data Demonstrate That Seno Medical’s Opto-Acoustic Imaging Technology Offers A Non-Invasive Approach to Differentiating Breast Cancer Molecular Subtypes

New Data Demonstrate That Seno Medical’s Opto-Acoustic Imaging Technology Offers A Non-Invasive Approach to Differentiating Breast Cancer Molecular Subtypes

” There are four distinct main molecular subtypes of breast cancer, which are defined based on the presence of hormone receptors (estrogen [ER] and progesterone [PR]) with or without human epidermal growth factor receptor 2 (HER2) protein overexpression or extra copies of the HER2 gene, and elevation of the ki67 proliferation marker. ...

BySeno Medical Instruments, Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical Equipment & Supplies
  • Medical Software
  • Medical Training Courses
  • Medical Industry Services
  • Medical Product Applications

Latest

  • Medical Industry News
  • Medical Industry Events

Publications

  • Medical Industry Articles & Case Studies
  • Medical Industry Books and Publications
  • Medical Industry Journals and Magazines
  • Medical Industry Downloads
  • Medical Industry Videos

Companies

  • Medical Industry Suppliers & Manufacturers

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT